Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.

The Journal of clinical investigation - 15 Jun 2022

Collins Michael T

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare, debilitating disease in which heterotopic bone is formed in certain soft tissues. A gain-of-function variant in the cytoplasmic domain of the activin A receptor type I (ACVR1) exists in all patients with FOP. Strikingly, these FOP-causing variants imbue a neofunction to ACVR1 - the ability to recognize activin A as an agonist with bone morphogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Biology
Share to Bone Morphogenetic Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 35703179
DOI: 10.1172/JCI160773
PMCID: PMC9197510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.PMID 35703179Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva emerges from obscurity.Semantic proximity Read ↗

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-DependentSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva miceSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva: a blueprint for metamorphosisSemantic proximity Read ↗

A Novel Gain-of-Function Mutation in BMPR2 in a Patient with Variant Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

A Door Opens for Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.